Top entities: CurifyLabs, Sandwater, HealthCap, Charlotta Topelius, United States.

What category does this event fall under?

Business — classified as funding round.

What is the sentiment of coverage?

Aggregate sentiment score: 30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

CurifyLabs raised Series A funding · Sandwater co-led funding round CurifyLabs · HealthCap co-led funding round CurifyLabs

Is this event still developing?

This is an active story, last updated Jul 08, 2026. Coverage continues to evolve.

Business funding round

CurifyLabs Raises $14M Series A

Q: When did this event occur?

First reported Jul 06, 2026; last updated Jul 08, 2026.

Q: What is the market impact?

General. The funding signals continued investor confidence in personalized medicine and 3D printing for pharmaceuticals.

Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 08, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The funding signals continued investor confidence in personalized medicine and 3D printing for pharmaceuticals. CurifyLabs' expansion in the U.S. may increase competition in the compounding pharmacy market, but the impact is limited given the company's niche focus.

healthcare pharmaceuticals 3D printing

Event Summary

CurifyLabs, a health technology company based in Helsinki and Jacksonville, announced the closing of a $14 million Series A funding round on July 6, 2026. The round was co-led by Sandwater and HealthCap, with participation from Tesi and existing investors including Lifeline Ventures. U.S. customers and employees also participated. The funds will be used to expand U.S. operations, strengthen supply chain infrastructure, enhance customer support, and accelerate product innovation. CurifyLabs' Compounding System Solution (CSS) combines proprietary software, GMP-manufactured excipient bases, and advanced 3D printing technology to automate personalized medication preparation. The technology is ISO 13485 certified and designed in compliance with FDA 503A/503B standards. The company's latest product, PharmaPrinter Aurum, compounds up to nine times faster than manual processes. CurifyLabs serves pharmacies in 21 U.S. states and across Europe, compounding thousands of doses daily.

Key Actions

100 CurifyLabs raised Series A funding

80 Sandwater co-led funding round CurifyLabs

80 HealthCap co-led funding round CurifyLabs

50 Lifeline Ventures participated in funding CurifyLabs

Entities Involved

priv

CurifyLabs

CurifyLabs raised $14M Series A to scale its personalized medicine platform, enhancing its ability to expand U.S. operations and develop new products.

Importance 100.0 Sentiment 70.0

priv

Sandwater

Sandwater co-led the funding round, supporting CurifyLabs' growth in personalized medicine.

Importance 50.0 Sentiment 30.0

priv

HealthCap

HealthCap co-led the funding round, adding CurifyLabs to its life sciences portfolio.

Importance 50.0 Sentiment 30.0

per

Charlotta Topelius

As CEO and Founder, Charlotta Topelius led the company to secure the Series A funding.

Importance 40.0 Sentiment 40.0

cnt

United States

CurifyLabs plans to expand its U.S. operations, serving pharmacies in 21 states.

Importance 30.0 Sentiment 10.0

priv

Lifeline Ventures

Lifeline Ventures, an existing investor, participated in the funding round.

Importance 20.0 Sentiment 20.0

per

Morten E. Iversen

Morten E. Iversen, partner at Sandwater, commented on the investment, highlighting CurifyLabs' technology.